Figure 2From: Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model Cytotoxicity of lapatinib in A549 cells exposed to different concentrations (0.05, 0.5 and 5 μM) of the drug, for 24 h and 72 h. At the indicated time point, cell viability was measured by MTT, indicating that lapatinib significantly reduces A549 cell proliferation (**: P < 0.01; ***:P < 0.001).Back to article page